Slide 1: Financial Results for the Quarter Ended March 31, 2018
For personal use only Financial Results for the Quarter Ended March 31, 2018 May 2018 Nasdaq: MESO ASX:MSB
Slide 2: Cautionary Note Regarding Forward-Looking Statements
For personal use only CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, le
Slide 3: Committed to bringing disruptive cellular medicines to market
For personal use only Mesoblast is committed to bringing to market disruptive cellular medicines to treat serious and life-threatening illnesses.
Slide 4: Premier global cellular medicines company
Premier global cellular medicines company For personal use only Disruptive Technology Industrial Scale Multiple Revenue Platform1 Manufacturing Generating Products & Phase 3 Assets • Immuno-selected, culture • Unique cell properties enable • 2 approved products expanded cellular medicines large scal
Slide 5: Clinical pipeline and products commercialized by licensees
Clinical pipeline and products commercialized by licensees For personal use only PLATFORM PRODUCT THERAPEUTIC AREA APPROVAL COMMERCIAL RIGHTS MARKETED MSC TEMCELL® Acute GVHD Japan Only (Bone Marrow) HS Inj1 MSC (Adipose) Alofisel2 Perianal Fistula World Wide PRODUCT PRE-CLINICAL PLATFORM THERAP
Slide 6: Financials
For personal use only Financials
Slide 7: Cash position and cash flows for the nine months ending March 31, 2018
Q3 FY18 Cash position and cash flows for the nine months ending March 31, 2018 (US$m) For personal use only March 31, 2018 March 31, 2017 $Change %Change Operating net cash (outflows)/inflows (54.8) (72.0) 17.2 24% Investing net cash (outflows)/inflows (0.7) 0.1 (0.8) NM Financing net cash inflows 6
Slide 8: Profit and Loss for the nine months ending March 31, 2018 (revenue)
Q3 FY18 Profit and Loss for the nine months ending March 31, 2018 (US$m) For personal use only For the nine months ending March 31, 2018 March 31, 2017 $Change % Revenue 15.6 1.8 13.8 NM Research and Development (48.4) (43.0) (5.4) (13%) Manufacturing Commercialization (3.4) (10.9) 7.5 69% Managemen
Slide 9: Profit and Loss for the nine months ending March 31, 2018 (loss)
Q3 FY18 Profit and Loss for the nine months ending March 31, 2018 (US$m) For personal use only For the nine months ending March 31, 2018 March 31, 2017 $Change % Revenue 15.6 1.8 13.8 NM Research and Development (48.4) (43.0) (5.4) (13%) Manufacturing Commercialization (3.4) (10.9) 7.5 69% Managemen
Slide 10: Disruptive cellular medicine technology
Disruptive cellular medicine technology For personal use only • STRO-1+ Mesenchymal Precursor Cells (MPCs) are at the apex of the hierarchy of Mesenchymal Lineage • STRO-1/STRO-3 immuno-selection provides a homogeneous population of MPCs with receptors that respond to activating inflammation and dam
Slide 11: Global IP estate provides substantial competitive advantage
Global IP estate provides substantial competitive advantage For personal use only • ~800 Patents and patent applications (69 Patent families) across all major jurisdictions • Covers composition of matter, manufacturing, and therapeutic applications of MLCs • Provides strong commercial protection for
Slide 12: Industrial scale manufacturing
Industrial scale manufacturing For personal use only • Immune privileged cellular technology platform enables allogeneic ‘off the shelf’ product candidates • Scalable culture expansion sufficient to produce anticipated commercial quantities • Proprietary media formulations, advances in development o
Slide 13: The 21st Century Cures Act (RMAT)
The 21st Century Cures Act (Cures Act) Regenerative Medicine Advanced Therapies (RMAT) For personal use only • Cellular medicines may be designated as regenerative advanced therapies, if they are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition, and ther
Slide 14: Clinical pipeline
Clinical pipeline For personal use only PRODUCT PRE-CLINICAL PLATFORM THERAPEUTIC AREA PHASE 2 PHASE 3 COMMERCIAL RIGHTS CANDIDATE / PRE- IND IN DEVELOPMENT MSC MSC-100-IV Acute GVHD FDA Fast Track Advanced HF (Class II & III) MPC MPC-150-IM End-Stage HF (Class III & IV)1 FDA RMAT TIER 1 MPC MPC-06-
Slide 15: CY 2018 corporate milestones
CY 2018 corporate milestones For personal use only MSC-100-IV for Acute Graft versus Host Disease • Successfully met Day 28 primary end point pediatric Phase 3 trial (Q1 CY18) • Day 100 survival/safety data pediatric Phase 3 trial (Q2 CY18) • Day 180 survival/safety data pediatric Phase 3 trial (Q
Slide 16: Questions
For personal use only Questions
Slide 17: Thank you
For personal use only Thank you